EIGR

Eiger BioPharmaceuticals, Inc. (EIGR) | Rumor.io

Eiger BioPharmaceuticals

EIGR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)18%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about EIGR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Apr 4

Eiger BioPharmaceuticals Inc ($EIGR) has gained 41.9% as of the post date, with a float of 39.1M and a short interest of 2.6%.
The stock's relative strength is improving, indicating potential for a rebound in the small-cap space.
Analysts advise caution, recommending waiting for consolidations before entering the market with defined risk.

Generated by AI

Sentiment

Of the messages about EIGR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0%	33.33% -20.51
Bearish	100%	100%	100%	66.67% +20.51

Topics

Of the messages about EIGR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	0%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	100%
Analysts	—	—	—	0%

Apr 1

Eiger BioPharmaceuticals, Inc. ($EIGR) has filed for voluntary Chapter 11 protection and entered into a "stalking horse" agreement for the sale of Zokinvy to Sentynl Therapeutics for up to $26M.
Trading for $EIGR has been halted multiple times on NASDAQ, with the stock experiencing significant price drops following the company's Chapter 11 bankruptcy protection filing.
Eiger BioPharmaceuticals has announced that access to Zokinvy will continue uninterrupted despite the Chapter 11 filing, and the company has secured a "stalking horse" agreement for the sale of the asset.

Generated by AI

Community

Of the messages about EIGR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	5.88%	57.72%
Newcomers	100%	100%	94.12%	42.28%

Regulars· Apr 4

EIGR is gaining momentum, up 15.2% pre-market, and is trending towards the target of $3.
The stock's float is 39.1M, and short interest is 2.6%, with a notable DYNAMOgapDOWN and volume radar.
EIGR is facing delisting from Nasdaq, and regulars advise against chasing the stock and instead recommend waiting for consolidations with defined risk.

Newcomers· Dec 28

New shareholders are criticizing Eiger Biopharmaceuticals, Inc. ($EIGR) for allegedly misleading investors about the viability of a Covid-19 treatment product candidate, and are encouraging others to join a class action lawsuit.
Some traders are celebrating the stock's price movement, posting about it ahead of the market opening, with one user using a rocket emoji to convey excitement.
A top analyst has set a price target for $EIGR, although the specific amount is not mentioned in the post.

Generated by AI

Also Discussed

Investors talking about EIGR also mention

#	Name	Attention
1	Solid Biosciences Inc.SLDB	0.3%new
2	Kubient Inc.KBNT	0%0
3	MYOV - Myovant Sciences Ltd.	——
4	Karyopharm Therapeutics Inc.KPTI	0%new
5	Crescent Biopharma Inc.GLYC	0%new
6	Clearside Biomedical Inc.CLSD	0%0
7	FUSN - Fusion Pharmaceuticals Inc.	——
8	Lucid Diagnostics Inc.LUCD	0%+0
9	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
10	ALBO - Albireo Pharma, Inc.	——